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Abstract
Background: HIV voluntary counselling and testing (VCT) is an integral component of HIV prevention and treatment
programmes. However, testing coverage in sub-Saharan Africa is still low, particularly among young people. As treatment
becomes more widely available, strategies to expand VCT coverage are critically important. We compare VCT uptake using
two delivery strategies (opt-in and opt-out) within the MEMA kwa Vijana trial in 20 communities in northwest Tanzania.
Methods: We analysed data from 12,590 young persons (median (IQR) age 22 years (20–23)) to assess the effect of delivery
strategy on VCT uptake. Ten communities used an opt-in approach and 10 used opt-out, balanced across intervention and
control. Conditional logistic regression was used to examine factors associated with uptake within each strategy.
Results: VCT uptake was significantly higher with the opt-out approach (90.9% vs 60.5%, prevalence ratio = 1.51, CI = 1.41–
1.62). Among females, uptake in the opt-out approach was associated with decreased knowledge of HIV acquisition, sex
with a casual partner, and being HSV-2 seronegative; among males, uptake was associated with lower education and
increasing lifetime partners. In contrast, uptake using the opt-in approach varied by ethnic group, religion and marital
status, and increased with increasing knowledge of STI acquisition (males) or pregnancy prevention (females).
Conclusion: VCT uptake among young people was extremely high when offered an opt-out strategy. Sociodemographic
and knowledge factors affected uptake in different ways depending on delivery strategy. Increased knowledge may increase
young persons’ self-efficacy, which may have a different impact on testing uptake, depending on the approach used.
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Introduction
As access to antiretroviral therapy (ART) becomes more widely
available for the treatment of HIV infection, expanding access to,
and use of, VCT is critically important.
‘Client-initiated’ VCT, where individuals proactively seek HIV
testing, remains the primary VCT model in many sub-Saharan
African countries. Its availability is constrained by a shortage of
skilled service providers and weak health infrastructure. Barriers to
uptake of client-initiated VCT include personal perceptions of risk,
negative perceptions of health services or of HIV testing services,
and fear of stigma and discrimination [1,2,3].
‘Provider-initiated’ testing and counselling (PITC) is an
alternative approach to VCT, where individuals are informed
that they will receive an HIV test as part of general medical
screening or clinical management unless they opt out. This model
has been promoted by WHO and UNAIDS to increase
opportunities for HIV diagnosis, and by 2009, two-thirds of
countries in sub-Saharan Africa had introduced policies support-
ing PITC [4].
Repeat population-based surveys in 9 African countries in
2003–2009 have shown an increase in VCT uptake in recent years
[4]. In Tanzania, an estimated 30% of women and 25% of men
aged 15–49 in 2009–2010 had been tested for HIV in the past 12
months, compared with 6% and 7%, respectively, in 2004–2005
[5]. However, in many countries in sub-Saharan Africa, VCT
uptake is lower among young people than in older age groups, and
the difference by age is greater among men than women [6],[7].
Between 1998–2008, a community-randomised controlled trial
was conducted in rural Tanzania to evaluate the impact of the
MEMA kwa Vijana (‘‘Good things for young people’’) adolescent
sexual and reproductive health intervention. The trial was
conducted in 20 communities, with 10 randomly chosen to
receive the intervention. Impact evaluations conducted 3 years
(2001/2) and 9 years (2007/8) after the start of the intervention
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demonstrated that it had led to an improvement in young people’s
sexual and reproductive health knowledge and reported attitudes
and in some reported sexual behaviours [8],[9]. However, no
significant impact was seen on the prevalence of HIV, other STIs
or pregnancies.
The trial intervention did not specifically aim to increase VCT
uptake and VCT uptake was not a pre-specified trial outcome.
However, in the 2007/8 follow-up survey, we compared VCT
uptake using an opt-in versus an opt-out approach, and examined
factors associated with uptake under each strategy. Since this was
not a main aim of the trial, communities were not randomised to
VCT delivery strategy, but were balanced in terms of intervention
and control arms within each VCT strategy.
Methods
Ethics
The trial protocol received ethical and research clearance from
the Tanzanian Medical Research Coordinating Committee and
the Ethics Committee of the London School of Hygiene and
Tropical Medicine. Signed informed consent was obtained from
each participant on the day of the survey. Additional written
consent was obtained from parents for participants under the age
of 18 years.
Study design
The overall MEMA kwa Vijana intervention and study design
have been described previously [10,11]. In 2007–2008, a cross-
sectional survey was conducted to evaluate the long-term impact of
the MEMA kwa Vijana intervention [9].
A household census in the 20 trial communities identified
potentially eligible young people who were invited to a survey at a
central location 2–3 days later. Young people who had attended
one or more of the last 3 years of primary school (standard 5, 6 or
7) in a school within a trial community between 1999–2002
inclusive were eligible for the survey.
Eligible individuals who gave informed consent were inter-
viewed on sexual knowledge, attitudes and behaviour in a 20–
30 minute structured questionnaire administered by a same-sex,
21–29 year-old research assistant. Laboratory samples (serum and
urine) were collected by trained technicians, and a clinician
checked for symptoms (males and females) and clinical signs (males
only) suggestive of STI.
The majority (91%) of participants were surveyed from June
2007–May 2008. However, in order to include additional eligible
young people, all trial communities, nearby secondary schools, and
major migration points within the Lake Zone of Tanzania were
revisited in June–July 2008. The survey teams for the re-visit phase
were different from those in the main phase, and used the opt-in
VCT delivery strategy only. For consistency, the analysis of VCT
uptake presented here includes only those participants seen by the
two trial survey teams during the main survey and excludes
participants who attended during the re-visit phase.
HIV counselling and testing
The interviews and clinical procedures were conducted by two
survey teams, with each team visiting 10 communities. In both
survey teams, VCT was offered to all participants as the final step
of the study visit, immediately after the interview and clinical
assessment were completed. Team 1 offered VCT using an opt-out
approach, whereby all participants saw a counsellor who offered
them HIV counselling and testing. Team 2 offered VCT using an
opt-in approach, whereby the main study interviewer told all
participants that they could visit a counselling room and see an on-
site counsellor in order to have an HIV test if they desired. Since
evaluation of effects on VCT uptake was not a primary aim of the
trial, communities were not randomised to VCT delivery strategy.
However, each survey team was allocated to 5 intervention and 5
control communities, so VCT delivery was balanced in terms of
the intervention and control arms. For logistical reasons,
communities that were in the same geographical area were visited
by the same team.
Each team had one trained male and one trained female
counsellor. VCT sessions were held in a separate, private room, at
the same location where the other study procedures were
conducted. Participants were informed about the service at the
start of the study visit.
Participants received one-to-one pre-test counselling; written
consent was obtained before testing. Blood was tested using two
parallel HIV rapid tests (SD Bioline HIV-1/2 3.0 (Standard
Diagnostics Inc) and Determine HIV1/2 (Abbott Laboratories)).
All participants received post-test counselling. Those who tested
positive were referred to the nearest health facility offering ART so
that their eligibility for treatment could be assessed, and were
provided with a referral letter and enough money to cover their
transport costs.
Questionnaire
As part of the main interview, participants were asked three
questions on each of three knowledge domains (HIV acquisition,
STI acquisition and pregnancy prevention), and three questions
related to their sexual attitudes [9]. A score was constructed for
each domain, ranging from 0 (no correct answers) to 3 (all answers
correct).
Participants were also asked about lifetime sexual behaviour,
sexual behaviours in the past 12 months, including detailed
information about the last three partners, contraception and
pregnancy.
Laboratory methods
The laboratory methods have been described elsewhere [9].
Briefly, sera were tested by HIV ELISA (Murex HIV 1.2.0, Murex
Biotech, UK; Vironostika HIV UniformII plusO, bioMe´rieux, the
Netherlands). Discordant or indeterminate samples were retested.
If results were not resolved on retesting, the sample was tested by
HIV-1 p24 Ag EIA (Biorad Genetic Systems, USA). P24 negative
samples were tested with a line immunoassay (INNO-LIATM HIV-
I/II, Innogenetics, Belgium). Sera were tested for antibodies to
HSV2 (Kalon HSV Type2 IgG ELISA, Kalon Biologicals,
Guildford, UK). Syphilis was tested using the Treponema pallidum
particle agglutination (TPPA) test (Serodia, Fujirebio, Japan).
Those positive on TPPA were tested for active syphilis using the
rapid plasma reagin (RPR) test (Immutrep, Omega Diagnostics,
Hillfoot, UK).
Statistical analysis
Data were double-entered and verified, and were analysed using
Stata 11. Participant characteristics were tabulated by study team
and compared using the Pearson chi-squared statistic with the
second-order correction of Rao and Scott to account for the
clustered design
We examined the effect of delivery strategy on the prevalence of
VCT uptake, using methods for cluster randomised trials [12].
Uptake was measured using prevalence ratios (PR), calculated as
the ratio of geometric mean prevalence of VCT uptake for the 10
communities in each strategy. The 95% confidence interval (CI)
was calculated using the residual mean square from a two-way
analysis of variance (ANOVA) of log prevalence on stratum and
VCT Uptake among Youth in HIV Prevention Trial
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strategy. Since communities were not randomised to VCT delivery
strategy (although they were balanced by intervention and
control), analyses were also adjusted for stratum, age group, sex,
ethnic group and education level. Adjusted prevalence ratios (aPR)
were calculated as the geometric mean ratio of observed to
expected events, with logistic regression used to estimate the
expected number of events, adjusted for individual-level covari-
ates.
Next we examined the effect of the MEMA kwa Vijana
intervention on overall VCT uptake, using the same method. In
addition, we did separate analyses within each survey team, to
evaluate the impact of the MEMA intervention on VCT uptake
within each delivery strategy.
Lastly, we investigated factors associated with VCT uptake
separately within each survey team. Since some of the associations
might have differed between men and women, all analyses were
stratified by sex. We used conditional logistic regression to estimate
odds ratios (OR) and 95% CI, conditioning on community to
account for within-community correlation. Potential determinants
of VCT uptake were examined using a conceptual framework with
four levels: sociodemographic factors, sexual knowledge and
attitudes, behavioural factors, and biological factors. First, socio-
demographic factors that were associated with VCT uptake at
p,0.10 were included in a multivariable model; those remaining
independently associated at p,0.10 were retained in a core model.
Sexual knowledge and attitude factors were added to this core
model one by one. Those that were associated with VCT uptake at
p,0.10, after adjusting for sociodemographic factors, were
included in a multivariable model and retained if they remained
significant at p,0.10. Associations of VCT uptake with behav-
ioural and then biological factors were determined in a similar
Table 1. Characteristics of study participants, by VCT strategy.
Opt-out strategy (Team 1,
N=5938) N (%)
Opt-in strategy (Team 2,
N=6652) N (%) p-value1
Sex
Female 2541 (42.8%) 3087 (46.4%) 0.02
Male 3397 (57.2%) 3565 (53.6%)
Age (years)
,21 2001 (33.7%) 2200 (33.1%) 0.43
21–22 1628 (27.4%) 1864 (28.0%)
23–24 1429 (24.1%) 1719 (25.8%)
$25 877 (14.8%) 869 (13.1%)
Currently married
Yes 2784 (46.9%) 2833 (42.6%) 0.18
Tribe
Sukuma 4290 (72.4%) 5779 (87.0%) 0.10
Non-Sukuma 1639 (27.6%) 867 (13.0%)
Religion
Christian 4854 (81.9%) 5704 (85.9%) 0.39
Muslim 326 (5.5%) 214 (3.2%)
None/traditional/other 744 (12.6%) 724 (10.9%)
Circumcised (males only)
Yes 1390 (42.0%) 1363 (38.5%)
Highest level of education
Secondary or higher 618 (10.4%) 1426 (21.5%) ,0.001
Main occupation
Business 825 (14.0%) 1230 (18.5%) 0.22
Fishing/farming 3572 (60.5%) 3892 (58.7%)
Student 1076 (18.2%) 1024 (15.4%)
None/other 432 (7.3%) 490 (7.4%)
Type of site/community
Farming/mainly farming 4700 (79.2%) 4955 (74.5%) 0.21
Fishing/mainly fishing 363 (6.1%) 513 (7.7%)
Trading centre 490 (8.3%) 1164 (17.5%)
Mining 385 (6.5%) 19 (0.3%)
HIV serostatus
Positive 144 (2.4%) 190 (2.9%) 0.32
1Rao-Scott F (second-order correction to the Pearson x2 statistic to account for clustered design).
doi:10.1371/journal.pone.0042108.t001
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way. The final model excluded factors one at a time until all
remaining factors were significant at p,0.05.
Results
Survey participants
In total 12,590 young persons (5628 females and 6962 males)
were surveyed from June 2007–May 2008 and were offered VCT.
Overall HIV prevalence was 2.9% (4.0% in females and 1.8% in
males). Team 1 (opt-out strategy) surveyed fewer participants than
Team 2 (5938 vs 6652, respectively), a higher proportion of males
(57% vs 54%, p= 0.02; Table 1), and lower proportion of Sukuma
ethnic group (72% vs 87%, p= 0.10). The median (IQR) age of
participants surveyed by each team was 22 (20–24) years. The
proportion with secondary education or above was lower in the
communities visited by Team 1 (10% vs 21%, p,0.001).
Otherwise the participants seen by each team were reasonably
similar.
Impact of strategy on VCT uptake
Overall, 9420 (74.8%) participants accepted VCT. VCT uptake
was significantly higher among participants offered the opt-out
strategy than those offered opt-in (90.9 vs 60.4%, p,0.001;
PR=1.51, CI = 1.41–1.62; Table 2). Uptake was higher with the
opt-out strategy in all age, sex and sociodemographic categories.
After adjusting for age, sex, ethnic group and education,
participants offered the opt-out strategy were much more likely
to accept testing than those offered the opt-in approach
(aPR=1.46, CI = 1.36–1.56).
Within each strategy, there was no evidence of a difference in
the proportion of males and females accepting VCT (91.0% vs
90.8%, respectively, using the opt-out strategy, p = 0.80; and
61.0% vs 59.8%, respectively, using the opt-in strategy, p = 0.53).
Impact of intervention on VCT uptake
There was no evidence of an impact of the MEMA kwa Vijana
intervention on VCT uptake overall, in either males or females
(PR=1.01, CI = 0.80–1.29 and PR=0.98, CI = 0.77–1.25, re-
spectively; Table 2). Furthermore, there was no evidence of an
impact of the intervention on VCT uptake with either strategy, or
after adjusting for individual-level covariates (Table 2).
Factors associated with VCT uptake in the opt-out
strategy (Team 1)
In females, in the unadjusted analysis, factors associated
(p,0.10) with VCT uptake using the opt-out strategy were
knowledge of HIV acquisition, sex with a casual partner in the past
12 months and being HSV-2 seronegative (Table 3). In the
multivariable analysis, only negative HSV2 serostatus remained
independently associated with VCT uptake at p,0.05
(aOR=0.74, CI = 0.56–0.98; Table 4). There was some evidence
that VCT uptake was higher among those reporting a casual
partner in the past 12 months (aOR=1.52, CI = 0.96–2.38), and
was inversely associated with knowledge of HIV acquisition
Table 2. Impact of MEMA kwa Vijana intervention and delivery strategy on VCT uptake in males & females.
EFFECT OF MEMA KWA VIJANA INTERVENTION
Intervention n/N (%) Comparison n/N (%) Unadjusted PR (95% CI)
Adjusted PR1 (95%
CI)
ALL PARTICIPANTS
VCT uptake 4873/6489 (75.1) 4547/6101 (74.5) 1.00 (0.78, 1.27) 0.99 (0.78, 1.25)
VCT uptake in Team 1 2822/3128 (90.2) 2577/2810 (91.7) 0.98 (0.94, 1.03) 0.98 (0.93, 1.03)
VCT uptake in Team 2 2051/3361 (61.0) 1970/3291 (59.9) 1.02 (0.85, 1.21) 1.02 (0.86, 1.22)
MALES
VCT uptake 2769/3630 (76.3) 2496/3332 (74.9) 1.01 (0.80, 1.29) 1.01 (0.80, 1.28)
VCT uptake in Team 1 1623/1790 (90.7) 1468/1607 (91.4) 0.99 (0.95, 1.03) 0.99 (0.94, 1.03)
VCT uptake in Team 2 1146/1840 (62.3) 1028/1725 (59.6) 1.04 (0.84, 1.29) 1.04 (0.84, 1.30)
FEMALES
VCT uptake 2104/2859 (73.6) 2051/2769 (74.1) 0.98 (0.77, 1.25) 0.97 (0.76, 1.23)
VCT uptake in Team 1 1199/1338 (89.6) 1109/1203 (92.2) 0.97 (0.92, 1.03) 0.98 (0.92, 1.04)
VCT uptake in Team 2 905/1521 (59.5) 942/1566 (60.2) 0.98 (0.86, 1.13) 0.99 (0.86, 1.14)
EFFECT OF DELIVERY STRATEGY
Opt-out strategy n/N (%) Opt-in strategy n/N (%) Unadjusted PR (95% CI) Adjusted PR2 (95% CI)
ALL PARTICIPANTS
VCT uptake 5399/5938 (90.9) 4021/6652 (60.4) 1.51 (1.41, 1.62) 1.46 (1.36, 1.56)
MALES
VCT uptake 3091/3397 (91.0) 2174/3565 (61.0) 1.50 (1.38, 1.62) 1.42 (1.31, 1.53)
FEMALES
VCT uptake 2308/2541 (90.8) 1847/3087 (59.8) 1.53 (1.42, 1.64) 1.50 (1.39, 1.62)
1Adjusted for sex (analysis in all participants), and stratum, age and tribe.
2Adjusted for sex (analysis in all participants), and stratum, age, tribe and education.
doi:10.1371/journal.pone.0042108.t002
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(aOR=0.77, CI = 0.57–1.05 comparing 3 correct vs 0–2 correct
answers).
In males, in the unadjusted analysis, factors associated with
VCT uptake using the opt-out strategy were lower education, high
lifetime number of partners, and a concurrent sexual partnership
or casual partner in the past 12 months (Table 3). In the
multivariable analysis, only lifetime number of partners remained
independently associated with VCT uptake (aOR=1.27,
CI = 0.84–1.90 for 5 or more partners vs one; Table 4). There
was some evidence that VCT uptake was higher among those with
lower education (aOR=1.55, CI = 1.10–2.19 for primary vs
secondary or above).
In both males and females, there was no evidence of an
association of an individual’s HIV serostatus with VCT uptake
using the opt-out strategy (Table 3).
Factors associated with VCT uptake in the opt-in strategy
(Team 2)
In females, in the unadjusted analysis, factors associated
(p,0.10) with VCT uptake using the opt-in strategy were non-
Sukuma ethnic group, religion (uptake highest among Christians
and lowest among those reporting traditional or no religion),
knowledge of pregnancy prevention, and past or current syphilis
infection (Table 3). In the multivariable analysis, factors that
remained independently associated with VCT uptake at p,0.05
were religion, increasing knowledge of pregnancy prevention
(aOR=1.29, CI = 1.10–1.51, comparing 3 vs 0–2 correct
answers), and current or past syphilis infection (aOR=2.06,
CI = 1.14–3.75 for past infection vs negative; Table 5). There was
weak evidence that uptake was higher among non-Sukuma, after
adjusting for other factors.
In males, in the unadjusted analysis, factors associated with
VCT uptake using the opt-in strategy were being married, religion
(uptake highest among Christians, and lowest among Muslims),
being uncircumcised, increased knowledge of HIV or STI
acquisition, increasing number of lifetime partners, having made
someone pregnant whilst still in primary school, travel outside the
community in the past 12 months, reporting a concurrent sexual
partnership or casual partner in the past 12 months, and current
syphilis infection (Table 3). In the multivariable analysis, factors
that remained independently associated with VCT uptake were
being married (aOR=1.25, CI = 1.07–1.46), religion, being
uncircumcised (aOR=1.28,–1.51), increasing knowledge of STI
acquisition (aOR=1.22, CI = 1.05–1.40, comparing 3 vs 0–2
correct answers), travel in the past 12 months (aOR=1.26,
CI = 1.08–1.47) and a casual sexual partner in the past 12 months
(aOR=1.25, CI = 1.09–1.44; Table 5).
In both males and females, there was no evidence of an
association of an individual’s HIV serostatus with VCT uptake
using the opt-in strategy (Table 3).
Discussion
We found that VCT uptake was significantly higher in the
communities offered the opt-out strategy than the opt-in approach,
in both males and females and in all age groups. The opt-out
strategy was associated with a 50% increase in the overall
prevalence of testing compared with the opt-in. Acceptance with
the opt-out strategy was extremely high (90%), with no evidence of
a difference by sex, age, or sociodemographic characteristics other
than education level in males. In contrast, VCT uptake with the
opt-in strategy varied among ethnic, religious or marital status
groups.
Table 4. Factors independently associated with acceptance of VCT using the opt-out strategy (Team 1).
Females (N=2541) Males (N=3397)
number accepting (%) Adjusted OR1 (95% CI) number accepting (%) Adjusted OR2 (95% CI)
Education P= 0.34 P=0.05
Secondary or higher 246 (89.1) 1 296 (86.6) 1
Primary 1976 (90.9) 1.17 [0.76, 1.82] 2737 (91.5) 1.55 [1.10, 2.19]
Incomplete primary 82 (94.3) 2.02 [0.74, 5.48] 54 (93.1) 1.77 [0.61, 5.15]
Knowledge on HIV acquisition P=0.09 P= 0.77
0–2 correct 858 (92.7) 1 132 (92.3) 1
3 correct 1444 (89.8) 0.77 [0.57, 1.05] 2137 (90.7) 0.96 [0.74, 1.25]
Lifetime number of partners P= 0.58 P=0.03
0 179 (92.8) 1.49 [0.80, 2.77] 292 (90.4) 0.97 [0.58, 1.60]
1 720 (90.3) 1 357 (90.6) 1
2 (F) or 2–4 (M) 659 (90.5) 1.02 [0.71, 1.46] 1231 (89.5) 0.84 [0.57, 1.23]
$3 (F) or $5 (M) 742 (91.2) 1.12 [0.78, 1.62] 1204 (92.9) 1.27 [0.84, 1.90]
Casual partner in past 12 m P=0.06 P= 0.26
No 1981 (90.5) 1 1714 (90.2) 1
Yes 327 (93.2) 1.52 [0.96, 2.38] 1377 (92.1) 1.17 [0.89, 1.53]
HSV-2 P=0.04 P= 0.22
Negative 1373 (92.1) 1 2258 (91.5) 1
Positive 920 (89.9) 0.74 [0.56, 0.98] 828 (91.0) 0.86 [0.66, 1.14]
1Adjusted for all factors associated (p,0.10) with VCT uptake in females (knowledge on HIV acquisition, casual partner in past 12 m, and HSV-2 serostatus, shown in
bold).
2Adjusted for all factors associated (p,0.10) with VCT uptake in males (education and lifetime partners, shown in bold).
doi:10.1371/journal.pone.0042108.t004
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Our results are consistent with other studies in sub-Saharan
Africa, which show VCT uptake to be much higher with opt-out
approaches than with client-initiated models [1,13,14,15]. Al-
though both VCT strategies in our study were researcher-initiated
within a community-based trial, and so are not the same as VCT
provision in non-research settings, some parallels can still be
drawn. With our opt-in strategy, participants needed to make an
active decision to seek out the VCT counsellor, with the chance
that they might be seen entering the counsellor’s room. With the
opt-out strategy, the potential for perceived stigma was likely to
have been reduced, since all participants were asked to visit the
counsellor as part of the study procedures. The Regai Dzive Shiri
(RDZ) trial of a multi-component adolescent HIV prevention
intervention in Zimbabwe found that young people expressed a
reluctance to test at a clinic because they were concerned it would
suggest to their parents that they were sexually active [16]. Similar
concerns could explain the lower uptake with the opt-in strategy in
our setting. Alternatively, participants may have been anxious to
get back to their daily activities, so chose not to prolong the study
procedures by visiting the counsellor, indicating that VCT was not
a high priority for them.
Despite this, we found that overall uptake of VCT, at 75%, was
much higher than has been reported by other studies in this age
group. In the RDZ trial, among those aged 18–24 years, uptake of
VCT offered immediately after survey participation was 27% [16].
In Tanzania, a multi-site community randomised trial of a multi-
component HIV prevention intervention including mobile VCT
services, reported testing uptake of 30% among persons aged 18–
32 years [17]. The extremely high uptake we found with the opt-
out approach is similar to that from studies of home-based VCT
delivery strategies that included adults of all ages [18,19,20,21].
For example, a trial of home-based versus clinic-based HIV
services in Uganda found that 89% of household members who
were present at the time of the home visit accepted VCT [22].
We found no evidence of an association of VCT uptake with
HIV serostatus, with either delivery strategy. Other studies have
Table 5. Factors independently associated with uptake of VCT using the opt-in strategy (Team 2).
Females (N=3087) Males (N=3565)
number accepting (%) Adjusted OR (95% CI)1 number accepting (%) Adjusted OR (95% CI)2
Currently married P = 0.58 P=0.004
No 809 (60.6) 1 1486 (59.8) 1
Yes 1038 (59.2) 0.96 [0.82, 1.11] 688 (63.7) 1.25 [1.07, 1.46]
Tribe P=0.09 P= 0.91
Sukuma 1598 (59.3) 1 1893 (61.4) 1
Non-Sukuma 249 (64.0) 1.24 [0.96,1.60] 279 (58.4) 0.99 [0.78, 1.25]
Religion P=0.004 P=0.003
Christian 1687 (60.9) 1 1819 (60.9) 1
Muslim 53 (54.1) 0.77 [0.51, 1.16] 59 (54.1) 0.70 [0.47, 1.03]
None/other 103 (48.1) 0.62 [0.46, 0.83] 252 (55.4) 0.73 [0.59, 0.90]
Circumcised (males only) P=0.003
Yes 782 (57.4) 1
No 1381 (63.4) 1.28 [1.09, 1.51]
Knowledge on pregnancy prevention P=0.002 P= 0.33
0–2 correct 564 (56.1) 1 524 (59.3) 1
3 correct 1277 (61.7) 1.29 [1.10, 1.51] 1644 (61.5) 1.08 [0.92, 1.28]
Knowledge on STI acquisition P = 0.35 P=0.007
0–2 correct 1208 (60.2) 1 1088 (59.4) 1
3 correct 633 (59.4) 0.93 [0.79,1.09] 1081 (62.8) 1.22 [1.05, 1.40]
Slept away in past 12 m P = 0.81 P=0.003
No 979 (59.0) 1 626 (56.5) 1
Yes 867 (60.9) 1.02 [0.88,1.19] 1546 (63.1) 1.26 [1.08, 1.47]
Casual partner in past 12 m P = 0.24 P=0.002
No 1581 (59.3) 1 931 (57.9) 1
Yes 266 (63.2) 1.14 [0.92, 1.41] 1243 (63.6) 1.25 [1.09, 1.44]
Syphilis P =0.01 P= 0.23
Negative 1702 (59.3) 1 2053 (61.0) 1
Current infection 100 (64.9) 1.32 [0.94, 1.87] 79 (70.5) 1.43 [0.94, 2.18]
Past infection 44 (74.6) 2.06 [1.14, 3.75] 41 (62.1) 1.08 [0.65, 1.82]
1Adjusted for all factors associated (p,0.10) with VCT uptake in females (tribe, religion, knowledge of pregnancy prevention, and syphilis infection).
2Adjusted for all factors associated (p,0.10) with VCT uptake in males (currently married, religion, circumcision, knowledge of STI acquisition, getting a girl pregnant in
primary school, travel away in the past year, casual sexual partnership in the past year, and active syphilis.
doi:10.1371/journal.pone.0042108.t005
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found an association between HIV status and testing strategy. In
the Uganda trial, HIV prevalence among those testing in clinics
was more than double that of those testing at home, suggesting
that participants who tested in clinics may have suspected that they
were HIV positive [22]. Similarly, in the RDZ trial, HIV
prevalence among those testing in clinics was nearly double that
in a researcher-initiated community setting [16]. However, since
both our VCT approaches were researcher-initiated with very
high uptake, our power to detect a difference in uptake by HIV
status was limited.
Within each VCT strategy, males were as likely to accept testing
as females. Although population-based surveys in many sub-
Saharan African countries show that fewer men than women
report ever having been tested for HIV, this may partly reflect
opportunities for women to test during pregnancy [4]. Studies of
research-initiated HIV testing do not suggest a consistent gender
gap in uptake. A randomised controlled trial in Zimbabwe
comparing workplace-based versus clinic-based VCT found no
differences in uptake between men and women within each arm
[23]. In the RDZ trial, although VCT uptake was lower among
males than females in the clinic, there was no difference in the
non-clinic based setting [16]. In a community-based survey in
Kisesa, Tanzania, VCT uptake in village-based, research-initiated
facilities was similar among males and females aged 15–24 years
(12 vs 11%) [24].
Interestingly, we found different factors associated with VCT
uptake within each strategy. With the opt-in approach, uptake
varied by socio-demographic characteristics. Among both males
and females, uptake was lower in those practising traditional or no
religion, and in Muslims, compared with Christians. In females,
uptake was slightly higher among non-Sukuma, and in males it
was higher among those who were married. In contrast, VCT
uptake under the opt-out strategy did not vary by these socio-
demographic characteristics. In the community-based survey in
Kisesa, Tanzania, uptake varied by ethnic group, and was lower
among individuals practising traditional religion [24].
With our opt-out approach, there was some evidence that
uptake was higher among females with lower knowledge of HIV
acquisition and males with lower education. This could indicate
lack of empowerment to decline VCT among those less educated,
or greater fear of stigma and reluctance to test among those with
more education. In contrast, in the opt-in strategy, uptake was
associated with increased knowledge of pregnancy prevention
(females) or STI acquisition (males), indicating that those with
higher knowledge may have been more empowered to choose
VCT. Hence, the higher level of self-efficacy resulting from better
education/knowledge may have a different impact on uptake,
depending on whether young persons need to actively choose (opt
in) or refuse (opt out) testing.
In both strategies, there was some evidence that testing uptake
was higher among participants reporting risky sexual behaviour.
With the opt-out approach, females reporting a casual partner and
males with$5 lifetime partners were somewhat more likely to test.
With the opt-in approach, females with past or active syphilis, and
males with a casual partner were more likely to test. These findings
are similar to those from Kisesa, where VCT uptake among both
males and females was associated with reporting a high-risk
partner in the past 12 months [24].
There are limitations to our study. Since communities were not
randomised to delivery strategy, there were imbalances in some
sociodemographic characteristics between the two groups, in
particular ethnic composition and education, which may have
affected uptake and biased our estimate of the impact of the opt-
out strategy. However, in the analysis adjusted for factors that
were imbalanced, our estimate of the effect of strategy on uptake
was almost unchanged, suggesting that there was no important
confounding by these factors. VCT uptake in our research setting
is likely to be context-specific, and the extent to which it can be
generalised beyond this setting is uncertain. When consenting to
the cross-sectional study, all participants agreed to provide a serum
sample for anonymous HIV testing (a primary trial outcome).
Thus, they may be different from young people in general who
might be more reluctant to have their HIV results known, even if
anonymised. Lastly, we did not collect data on the participants’
perceptions of the acceptability of either VCT approach, so we
cannot evaluate our results in the light of the views of the
participants. Despite these limitations, our results demonstrate that
a very high uptake of VCT among young persons in rural
communities in Tanzania is feasible and acceptable.
Lastly, our findings have implications for universal voluntary
testing programmes with immediate treatment (test-and-treat) for
the prevention of HIV transmission. The barriers to testing that
we identified when using the opt-in approach were no longer
apparent when we used an opt-out approach, resulting in a
consistently high uptake across the community.
In conclusion, VCT uptake among young people was extremely
high when offered within a community-based opt-out strategy in
this research context. Sociodemographic and behavioural factors
affected uptake in different ways depending on the delivery
strategy. Alternative approaches to increase the uptake of VCT
among young persons are needed; our results indicate that opt-out
strategies may contribute towards this goal.
Acknowledgments
We thank the study participants, and the intervention, survey, data,
laboratory, social science and administrative staff in London and Mwanza
for both the first and second phase of the trial. Additionally we thank the
trial’s steering, scientific advisory, and data and safety monitoring
committees. We also thank the Tanzanian Ministries of Health and of
Education, National AIDS Control Programme, and Medical Research
Co-ordinating Committee, and the Ethics Committee of the LSHTM, for
permission to carry out and publish the results of this study. We are also
grateful to the Regional Medical and Education Officers of Mwanza and
the National Directors of NIMR and AMREF for their support.
Author Contributions
Conceived and designed the experiments: AMD JC DWJ RH DR.
Performed the experiments: AMD KM. Analyzed the data: KB. Wrote the
paper: KB AMD JC KM DWJ RH DR. Coordinated the long-term
evaluation phase of the trial in Mwanza (2006–2008): AMD. Was a PI and
contributed to all aspects of the trial throughout (1997–2008) and lead PI
for the long-term evaluation phase: DR.
References
1. Creek TL, Ntumy R, Seipone K, Smith M, Mogodi M, et al. (2007) Successful
introduction of routine opt-out HIV testing in antenatal care in Botswana.
J Acquir Immune Defic Syndr 45: 102–107.
2. Nakanjako D, Kamya M, Daniel K, Mayanja-Kizza H, Freers J, et al. (2007)
Acceptance of routine testing for HIV among adult patients at the medical
emergency unit at a national referral hospital in Kampala, Uganda. AIDS Behav
11: 753–758.
3. Kalichman SC, Simbayi LC (2003) HIV testing attitudes, AIDS stigma, and
voluntary HIV counselling and testing in a black township in Cape Town, South
Africa. Sex Transm Infect 79: 442–447.
4. WHO UNAIDS, UNICEF(2010) Towards universal access: scaling up priority
HIV/AIDS interventions in the health sector. Progress Report.
VCT Uptake among Youth in HIV Prevention Trial
PLoS ONE | www.plosone.org 9 July 2012 | Volume 7 | Issue 7 | e42108
5. National Bureau of Statistics (NBS) Tanzania and ICF Macro (2011) Tanzania
demographic and health survey 2010. Dar es Salaam, Tanzania: NBS and ICF
Macro.
6. WHO UNAIDS, UNICEF(2011) Global HIV/AIDS response: epidemic update
and health sector progress towards universal access. Progress Report.
7. WHO (2007) Access to health services for young people for preventing HIV and
improving sexual and reproductive health. Department of Child and Adolescent
Health and Development (CAH) Available: http://www.who.int/maternal_
child_adolescent/data/media/adolescent_health_service_indicators_all.pdf.
8. Ross DA, Changalucha J, Obasi AI, Todd J, Plummer ML, et al. (2007)
Biological and behavioural impact of an adolescent sexual health intervention in
Tanzania: a community-randomized trial. AIDS 21: 1943–1955.
9. Doyle AM, Ross DA, Maganja K, Baisley K, Masesa C, et al. (2010) Long-term
biological and behavioural impact of an adolescent sexual health intervention in
Tanzania: follow-up survey of the community-based MEMA kwa Vijana trial.
PLoS Medicine 7: e1000287.
10. Hayes RJ, Changalucha J, Ross DA, Gavyole A, Todd J, et al. (2005) The
MEMA kwa Vijana project: design of a community randomised trial of an
innovative adolescent sexual health intervention in rural Tanzania. Contemp
Clin Trials 26: 430–442.
11. Obasi AI, Cleophas B, Ross DA, Chima KL, Mmassy G, et al. (2006) Rationale
and design of the MEMA kwa Vijana adolescent sexual and reproductive health
intervention in Mwanza Region, Tanzania. AIDS Care 18: 311–322.
12. Hayes RJ and Moulton LH (2009) Cluster Randomised Trials. Boca Raton,
Florida: Chapman and Hall/CRC. 315 p.
13. Bassett IV, Giddy J, Nkera J, Wang B, Losina E, et al. (2007) Routine voluntary
HIV testing in Durban, South Africa: the experience from an outpatient
department. J Acquir Immune Defic Syndr 46: 181–186.
14. Leon N, Naidoo P, Mathews C, Lewin S, Lombard C (2010) The impact of
provider-initiated (opt-out) HIV testing and counseling of patients with sexually
transmitted infection in Cape Town, South Africa: a controlled trial. Implement
Sci 5: 8.
15. Pope DS, Deluca AN, Kali P, Hausler H, Sheard C, et al. (2008) A cluster-
randomized trial of provider-initiated (opt-out) HIV counseling and testing of
tuberculosis patients in South Africa. J Acquir Immune Defic Syndr 48: 190–
195.
16. Chirawu P, Langhaug L, Mavhu W, Pascoe S, Dirawo J, et al. (2010)
Acceptability and challenges of implementing voluntary counselling and testing
(VCT) in rural Zimbabwe: evidence from the Regai Dzive Shiri Project. AIDS
Care 22: 81–88.
17. Khumalo-Sakutukwa G, Morin SF, Fritz K, Charlebois ED, van Rooyen H, et
al. (2008) Project Accept (HPTN 043): a community-based intervention to
reduce HIV incidence in populations at risk for HIV in sub-Saharan Africa and
Thailand. J Acquir Immune Defic Syndr 49: 422–431.
18. Were W, Mermin J, Bunnell R, Ekwaru JP, Kaharuza F (2003) Home-based
model for HIV voluntary counselling and testing. Lancet 361: 1569.
19. Matovu JK, Makumbi FE (2007) Expanding access to voluntary HIV
counselling and testing in sub-Saharan Africa: alternative approaches for
improving uptake, 2001–2007. Trop Med Int Health 12: 1315–1322.
20. Mbopi-Keou FX, Ongolo-Zogo P, Angwafo F, Ndumbe PM, Belec L (2007)
High impact of mobile units for mass HIV testing in Africa. Aids 21: 1994–1996.
21. Fylkesnes K, Siziya S (2004) A randomized trial on acceptability of voluntary
HIV counselling and testing. Trop Med Int Health 9: 566–572.
22. Lugada E, Levin J, Abang B, Mermin J, Mugalanzi E, et al. (2010). Comparison
of home and clinic-based HIV testing among household members of persons
taking antiretroviral therapy in Uganda: results from a randomized trial. J Acquir
Immune Defic Syndr 55: 245–252.
23. Corbett EL, Dauya E, Matambo R, Cheung YB, Makamure B, et al. (2006)
Uptake of workplace HIV counselling and testing: a cluster-randomised trial in
Zimbabwe. PLoS Med 3: e238.
24. Wringe A, Isingo R, Urassa M, Maiseli G, Manyalla R, et al. (2008) Uptake of
HIV voluntary counselling and testing services in rural Tanzania: implications
for effective HIV prevention and equitable access to treatment. Trop Med Int
Health 13: 319–327.
VCT Uptake among Youth in HIV Prevention Trial
PLoS ONE | www.plosone.org 10 July 2012 | Volume 7 | Issue 7 | e42108
